netFormulary NHS
NHS Herefordshire Clinical Commissioning Group
Wye Valley NHS Trust
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
08.01.05  Expand sub section  Other antineoplastic drugs
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Arsenic trioxide
08.01.05  Expand sub section  Bevacizumab
08.01.05  Expand sub section  Bexarotene to top
08.01.05  Expand sub section  Bortezomib
08.01.05  Expand sub section  Brentuximab vedotin
08.01.05  Expand sub section  Cetuximab
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
08.01.05  Expand sub section  Erlotinib
08.01.05  Expand sub section  Hydroxycarbamide
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
08.01.05  Expand sub section  Mitotane to top
08.01.05  Expand sub section  Panitumumab
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine to top
08.01.05  Expand sub section  Protein kinase inhibitors
Cabozantinib (Cometriq)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
Cancer Drugs Fund

Oral cancer drug (NHSE commissioned)

 

 
Link  NICE TA463 : Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
   
Dasatinib (Sprycel)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

Oral cancer drug (NHSE commissioned)

 

 
Link  NICE TA241: CML where treatment with imatinib has failed
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Erlotinib (Tarceva)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
NHS England

Oral cancer drug (NHSE commissioned)

 

 
   
Gefitinib (Iressa)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
NHS England

Oral cancer drug (NHSE commissioned)

 
Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Cytotoxic Drug Imatinib (Gilvec)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
NHS England

 Restricted: NICE approved for CML (philidephia chromosome + ve)

 
   
Nilotinib (Tasigna)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine

Oral cancer drug (NHSE commissioned)

 

 
Link  NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Link  NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Regorafenib (Stivarga )
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Link  NICE TA514: Regorafenib for previously treated advanced hepatocellular carcinoma
   
Sorafenib (Nexavar)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund

Oral cancer drug NHSE commissioned

 
Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
   
Sunitinib (Sutent)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund

Oral cancer drug (NHSE commissioned)

 
Link  NICE TA169: Renal cell carcinoma - sunitinib
Link  NICE TA179: Gastrointestinal stromal tumours - sunitinib
Link  NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
   
Tivozanib
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Red

Oral cancer drug (NHSE commissioned)

 
Link  NICE TA512: Tivozanib for treating advanced renal cell carcinoma
   
08.01.05  Expand sub section  Taxanes
08.01.05  Expand sub section  Topoisomerase I inhibitors
08.01.05  Expand sub section  Trabectedin
08.01.05  Expand sub section  Trastuzumab to top
08.01.05  Expand sub section  Tretinoin
08.01.05  Expand sub section  Vismodegib
 ....
 Non Formulary Items
Afatinib  (Giotrif)

View adult BNF View SPC online View childrens BNF
Non Formulary
Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
 
Crizotinib  (Xalkori)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Cancer Drugs Fund
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance
Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
 
Everolimus  (Afinitor)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Cancer Drugs Fund
Link  NICE TA348: Preventing Rejection in Liver Transplant
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
 
Everolimus  (Votubia)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Link  NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
 
Lapatinib  (Tyverb)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
 
Pazopanib  (Votrient)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Link  NICE TA215: Pazopanib in renal cell cancer
 
Cytotoxic Drug  Temsirolimus  (Torisel)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Cancer Drugs Fund
 
Cytotoxic Drug  Vandetanib  (Caprelsa)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Cancer Drugs Fund
 
Vemurafenib  (Zelboraf)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Link  NICE TA269: Vemurafenib for treating malignant melanoma
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Suitable for use in primary care  

Amber

Specialist initiation. Shared care in place  

Red

Red do not use..  

Advice

Some formulations restricted  

Black

NICE "Do not do"  

Green 1

1st line option  

Green 2

2nd line option  

Green 3

3rd line option only  

Not Recomended / Black

Low Value Medicine not recommended for use - see NHSE guidelines  

OTC

This preparation should be bought over the counter for self-care  

Red Amber

Check product description for traffic light status  

Red Black

Low Value Medicine  

netFormulary